Eric S Daar Selected Research

Therapeutics

4/2024	Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
3/2024	Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial.
11/2023	Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial.
10/2023	One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
10/2023	Proprotein convertase subtisilin/kexin 9 (PCSK9) levels decline with HCV therapy in people with HIV/HCV and correlate with inflammation.
9/2023	Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
3/2023	Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
1/2023	ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
1/2023	Leveraging Multi-Ancestry Polygenic Risk Scores for Body Mass Index to Predict Antiretroviral Therapy-Induced Weight Gain.
1/2023	Long COVID After Bamlanivimab Treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric S Daar Research Topics

Disease

36	Infections 03/2024 - 10/2002
32	COVID-19 05/2024 - 09/2021
26	Acquired Immunodeficiency Syndrome (AIDS) 10/2021 - 11/2005
12	HIV Infections (HIV Infection) 03/2024 - 03/2004
10	Viremia 01/2023 - 01/2005
7	Inflammation (Inflammations) 10/2023 - 08/2005
6	Disease Progression 05/2024 - 08/2005
4	Virus Diseases (Viral Diseases) 04/2024 - 12/2010
3	Substance-Related Disorders (Drug Abuse) 10/2021 - 04/2008
3	Insulin Resistance 01/2019 - 04/2010
3	Brain Injuries (Brain Injury) 01/2019 - 01/2013
3	Persistent Infection 07/2014 - 05/2005
2	Weight Gain 01/2023 - 10/2021
2	AIDS Dementia Complex 01/2019 - 01/2013
2	Coinfection 07/2017 - 01/2016
2	Hyperbilirubinemia 04/2014 - 02/2013
2	Cognitive Dysfunction 01/2013 - 08/2011
2	Body Weight (Weight, Body) 12/2007 - 04/2004
2	Superinfection 11/2006 - 01/2005
2	Drug-Related Side Effects and Adverse Reactions 09/2004 - 08/2004
1	Post-Acute COVID-19 Syndrome 01/2023
1	Genetic Risk Score 01/2023
1	Chronic Hepatitis B 12/2022
1	Diabetes Mellitus 10/2022
1	Hyperglycemia 10/2022

Drug/Important Bio-Agent (IBA)

28	RNA (Ribonucleic Acid)IBA 10/2023 - 06/2005
14	Monoclonal AntibodiesIBA 05/2024 - 12/2021
14	efavirenz (Sustiva)FDA Link 10/2021 - 12/2007
13	Tenofovir (Viread)FDA Link 12/2022 - 12/2009
12	Emtricitabine (Emtriva)FDA Link 01/2019 - 12/2009
10	Atazanavir Sulfate (Reyataz)FDA Link 01/2019 - 12/2009
10	Ritonavir (Norvir)FDA Link 01/2019 - 03/2004
9	Antiviral Agents (Antivirals)IBA 05/2024 - 09/2021
8	bamlanivimabIBA 11/2023 - 09/2021
8	VaccinesIBA 01/2023 - 01/2005
8	lamivudine drug combination abacavir FDA Link 01/2019 - 12/2009
6	EpitopesIBA 11/2023 - 01/2005
5	Protease Inhibitors (Protease Inhibitor)IBA 01/2019 - 03/2004
5	Reverse Transcriptase InhibitorsIBA 01/2018 - 04/2008
4	Biomarkers (Surrogate Marker)IBA 01/2023 - 02/2014
4	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 10/2002
3	abacavir (Ziagen)FDA Link 10/2021 - 02/2015
3	tenofovir alafenamideIBA 01/2018 - 04/2016
3	NucleosidesIBA 01/2018 - 04/2008
3	RacivirIBA 09/2014 - 10/2011
3	Peptide Hydrolases (Proteases)FDA Link 12/2012 - 04/2008
3	Amino Acids FDA Link 12/2012 - 03/2004
2	romlusevimabIBA 05/2024 - 01/2023
2	amubarvimabIBA 05/2024 - 01/2023
2	Messenger RNA (mRNA)IBA 11/2023 - 01/2016
2	Viral RNAIBA 10/2023 - 08/2022
2	Neutralizing AntibodiesIBA 10/2023 - 11/2006
2	nirmatrelvir and ritonavir drug combinationIBA 01/2023 - 08/2022
2	Immunoglobulin G (IgG)IBA 01/2023 - 12/2022
2	Insulin (Novolin)FDA Link 10/2022 - 06/2014
2	Glucose (Dextrose)FDA LinkGeneric 10/2022 - 06/2014
2	AntigensIBA 12/2021 - 01/2008
2	Cytochrome P-450 CYP2B6 (CYP2B6)IBA 10/2021 - 12/2012
2	Mitochondrial DNA (mtDNA)IBA 01/2019 - 02/2013
2	bictegravirIBA 01/2018 - 11/2017
2	HLA-B Antigens (HLA-B)IBA 11/2017 - 08/2005
2	CytokinesIBA 01/2016 - 08/2005
2	CreatinineIBA 09/2015 - 03/2014
2	Cystatin CIBA 06/2015 - 03/2014
2	NucleotidesIBA 09/2014 - 10/2013
2	Proteins (Proteins, Gene)FDA Link 07/2014 - 12/2010
2	Methamphetamine (Desoxyn)FDA LinkGeneric 04/2008 - 11/2006
2	EnzymesIBA 01/2008 - 08/2005
1	Broadly Neutralizing AntibodiesIBA 03/2024
1	ogalvibartIBA 01/2024
1	crexavibartIBA 01/2024
1	Therapeutic UsesIBA 11/2023
1	camostatIBA 10/2023
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 10/2023
1	LDL CholesterolIBA 10/2023
1	oxidized low density lipoproteinIBA 10/2023
1	cilgavimabIBA 01/2023
1	Genetic Markers (Genetic Marker)IBA 01/2023
1	ZincIBA 01/2023
1	tixagevimabIBA 01/2023
1	SAB-185IBA 01/2023
1	Immunoglobulins (Immunoglobulin)IBA 01/2023
1	COVID-19 VaccinesIBA 01/2023
1	PlacebosIBA 01/2023
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2022
1	Oxygen (Dioxygen)IBA 10/2022
1	Nucleic AcidsIBA 12/2021
1	ChAdOx1 nCoV-19IBA 12/2021
1	IntegrasesIBA 10/2021
1	Integrase InhibitorsIBA 10/2021
1	theasinensin AIBA 01/2021
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 01/2020

Therapy/Procedure

51	Therapeutics 04/2024 - 04/2004
7	Art Therapy 03/2024 - 07/2014
4	Highly Active Antiretroviral Therapy (HAART) 05/2015 - 04/2004
3	Drug Therapy (Chemotherapy) 01/2018 - 01/2005
2	Renal Dialysis (Hemodialysis) 05/2007 - 08/2005
1	Intravenous Administration 01/2024
1	Aftercare (After-Treatment) 01/2023
1	Investigational Therapies (Experimental Therapy) 11/2022